Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.50 |
| ▸ | HTR2C | P28335 | 6/20 | 0.50 |
| ▸ | HTR2B | P41595 | 6/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6169947 | 0.76 | SIGMAR1 (0.47) | SIGMAR1 | |
| SCHEMBL7706950 | 0.76 | SIGMAR1 (0.47) | SIGMAR1 | |
| SCHEMBL22879323 | 0.75 | HTR2A (0.37) | HTR2AHTR2CHTR2BHRH3CYP1A2 | |
| SCHEMBL8584826 | 0.73 | HTR2A (0.47) | HTR2AHTR2CHTR2BHRH3ANPEP | |
| SCHEMBL12162771 | 0.73 | ANPEP (0.40) | HTR2AHTR2CHTR2BHRH3ANPEP | |
| SCHEMBL11460515 | 0.73 | SIGMAR1 (0.56) | HTR2AHTR2CHTR2BHRH3PRCP | |
| SCHEMBL6587468 | 0.72 | PARP1 (0.46) | HTR2AHTR2CHTR2BHRH3ACHE | |
| SCHEMBL7993604 | 0.72 | SIGMAR1 (0.41) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL7709439 | 0.72 | SIGMAR1 (0.47) | SIGMAR1 | |
| SCHEMBL8051810 | 0.72 | SIGMAR1 (0.47) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017458-B2 | Therapeutic tetrahydronaphthalene compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-07-10 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| EP-2427183-A2 | THERAPEUTIC COMPOUNDS | University of Florida Research Foundation, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129048-A2 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129048-A2 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | HTR2A 7/4885HTR2C 1/4885HTR2B 21/4885 |
| US-10017458-B2 | Therapeutic tetrahydronaphthalene compounds | HTR2C, HTR2A, HTR3C | HTR2A 2/4885HTR2C 1/4885HTR2B 12/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | HTR2A 7/4885HTR2C 1/4885HTR2B 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.